Bio-Rad Laboratories, Inc. (BIO) Position Maintained by Advantus Capital Management Inc

Advantus Capital Management Inc continued to hold its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) during the first quarter, Holdings Channel reports. The fund owned 2,627 shares of the medical research company’s stock at the end of the first quarter. Advantus Capital Management Inc’s holdings in Bio-Rad Laboratories were worth $524,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Advisory Services Network LLC acquired a new stake in Bio-Rad Laboratories during the first quarter worth about $115,000. Flinton Capital Management LLC increased its stake in Bio-Rad Laboratories by 17.6% in the first quarter. Flinton Capital Management LLC now owns 640 shares of the medical research company’s stock worth $128,000 after buying an additional 96 shares during the period. Meadow Creek Investment Management LLC increased its stake in Bio-Rad Laboratories by 17.6% in the first quarter. Meadow Creek Investment Management LLC now owns 880 shares of the medical research company’s stock worth $175,000 after buying an additional 132 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its stake in Bio-Rad Laboratories by 6.8% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,020 shares of the medical research company’s stock worth $176,000 after buying an additional 65 shares during the period. Finally, Dowling & Yahnke LLC acquired a new stake in Bio-Rad Laboratories during the first quarter worth about $201,000. 63.85% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) traded up 0.28% during mid-day trading on Tuesday, reaching $225.65. 29,970 shares of the company’s stock traded hands. Bio-Rad Laboratories, Inc. has a 1-year low of $135.94 and a 1-year high of $230.40. The firm has a 50-day moving average price of $222.28 and a 200-day moving average price of $200.51. The company has a market capitalization of $6.68 billion, a P/E ratio of 239.54 and a beta of 0.88.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Thursday, May 4th. The medical research company reported $0.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.14. Bio-Rad Laboratories had a return on equity of 3.23% and a net margin of 1.35%. The firm had revenue of $500.05 million during the quarter, compared to analyst estimates of $477.76 million. During the same period in the previous year, the company earned $0.42 EPS. The company’s revenue for the quarter was up 6.1% on a year-over-year basis. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post $2.85 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Bio-Rad Laboratories, Inc. (BIO) Position Maintained by Advantus Capital Management Inc” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/2655485/bio-rad-laboratories-inc-bio-position-maintained-by-advantus-capital-management-inc.html.

A number of analysts recently issued reports on the stock. Jefferies Group LLC reissued a “buy” rating and set a $250.00 target price on shares of Bio-Rad Laboratories in a research report on Thursday, April 27th. BidaskClub downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 14th. Finally, Zacks Investment Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Monday, March 27th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $217.25.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “BIO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
Shares at Radius Jump as Bone Drug of Amgen Has Setback
Shares at Radius Jump as Bone Drug of Amgen Has Setback


© 2006-2017 Ticker Report. Google+.